Safety and Efficacy of Cariprazine in Patients With Schizophrenia

Inclusion Criteria:

- Patients who have provided informed consent prior to any study specific procedures

- Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type,
disorganized type, catatonic type or undifferentiated type), as confirmed by the
Structured Clinical Interview for Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (SCID)

- Patients with normal physical examination, laboratory, vital signs,and/ or
electrocardiogram (ECG)

- Current psychotic episode (schizophrenia exacerbation) < 2 weeks duration at Visit 1

- Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCIPANSS)
total score ≥ 80 and ≤ 120

- CGI-S score ≥ 4

Exclusion Criteria:

- Schizoaffective disorder, schizophreniform disorder, and other psychotic disorders

- Bipolar I and II disorder

- Pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and
other cognitive disorders

- DSM-IV-TR axis II disorder of sufficient severity to interfere with participation in
this study

- Women who are pregnant or breast feeding